AETHLON MEDICAL AGM 2026

Thank you. Good morning, everyone. My name is James Frakes, and I'm the Chief Executive Officer and Chief Financial Officer of Aethlon Medical, Inc. I'm pleased to welcome you to the Aethlon Medical Annual Meeting of Stockholders. The meeting will now officially come to order. The time is now approximately 8:00 A.M. Pacific Time on October 1st, 2026, and the polls are now open for voting on all matters to be presented. As you know, we have adopted a virtual format for our annual meeting this year in order to provide a consistent and convenient experience to all stockholders, regardless of location. Before we proceed with the formal business of the meeting, I'd like to introduce to you the members of the business team who are with us today. The other officer of the company with us virtually today is Michele Bombardiere, VP Controller.

I would also like to introduce Jennifer Trowbridge of Procopio, Cory, Hargreaves & Savitch LLP, the company's outside legal counsel, who is also in attendance virtually and is available to respond to appropriate questions as needed. Ms. Trowbridge will be serving as Inspector of Election and Secretary of the annual meeting. We will now proceed with the formal business of the meeting in the order set forth in the notice of annual meeting and proxy statement. We will first present the proposals submitted for stockholder approval by our board. We will take questions related to the proposals after all the proposals have been presented, after which we will announce the preliminary results of the voting. As I mentioned earlier, the polls are open for voting on all matters to be presented.

Each share of common stock issued and outstanding as of the close of business on August 10th, 2026, the record date for the annual meeting, is entitled to one vote on each matter to be presented. After I describe each item to be voted on, we will close the polls. We will not accept ballots, proxies, revocations, or changes after the closing of the polls. If you have already submitted your vote by proxy and do not wish to change your vote, you do not need to vote now, and your shares will be voted as you previously instructed. If you intend to vote and have not already done so, or you desire to change your vote, you must submit your vote online now. If you have not voted, I encourage you to vote online now to ensure that your vote is counted.

If you hold your shares through a bank, broker or other nominee, you must follow the directions you receive from them in order to vote or to change your previously submitted vote. Stockholders of record and registered beneficial owners may submit questions or comments for the Q&A portion of the meeting. Questions can be submitted by email to me, James Frakes, CEO and CFO of Aethlon Medical, at jfrakes@aethlonmedical.com. We will try to answer questions submitted that are germane to the proposals and/or this meeting as and if we have time. I will screen incoming questions, and during the Q&A portion of the meeting, will read germane questions out loud before someone from our team responds. Please submit your questions now to make sure they are received in timely fashion for our review and response.

Will the Secretary of the meeting please report at this time with respect to the mailing of the notice of the meeting and the stockholders list?

Thank you. At this time, I am appointing Ms. Trowbridge to act as Inspector of Election of this meeting. Ms. Trowbridge has taken and subscribed the customary oath of office to execute her duties with strict impartiality. We will file this oath with the records of the meeting. Her function is to decide upon the qualifications of voters, accept their votes, and when balloting on all matters is completed, to tally the final votes. Will the Secretary please report at this time with respect to the existence of a quorum?

Thank you. Accordingly, we will now proceed with the formal business of this meeting. After all of the proposals have been described, we will answer any questions related to the proposals submitted. As a reminder, we ask that any questions or comments during this portion of the meeting pertain only to these proposals. Please submit any questions as soon as possible for our review. There are 10 proposals to be considered by the stockholders of this meeting. The first item of business is the election of five directors to serve until the annual meeting of stockholders in 2027, and until their successors are elected. The nominees for director are Edward G. Broenniman, James B. Frakes, Nicolas Gikakis, Angela Rossetti, and Chetan S. Shah, MD. The second item of business today is the ratification of the appointment of Haskell & White LLP as our independent registered accounting firm for the fiscal year ending March 31, 2027.

The third item of business is the approval of an issuance of up to 1,126,602 shares of the company's common stock, issuable upon the exercise of common warrants and placement warrants issued pursuant to the company's offering in July 2006. The fourth item of business is the approval of the compensation of our named executive officers as disclosed in the proxy statement. The fifth item of business is the approval of an amendment to our 2020 Equity Incentive Plan, as amended, to increase the number of shares of our common stock authorized for issuance thereunder by 100,000 shares.

The sixth item of business is the approval of an amendment to our articles of incorporation to increase the number of authorized shares of our common stock from 20 million to 200 million. The seventh item of business is the approval of an amendment to our articles of incorporation to authorize 20 million shares of preferred stock and to authorize the board of directors to establish one or more series thereof, and to fix the designations, powers, preferences, rights, qualifications, limitations, and restrictions of each such series. The eighth item of business is the approval of an issuance of the company's common stock, or securities convertible into or exercisable for shares of the company's common stock in connection with one or more future private financing transactions.

The ninth item of business is the approval of an issuance of the company's common stock and/or securities exercisable for shares of the company's common stock in connection with one or more warrant exercise inducement transactions, including certain outstanding warrants of the company. The tenth and final item of business is the approval of an adjournment of the annual meeting to another place or a later date or dates, if necessary or appropriate, to solicit additional proxies in the event we have not received sufficient votes in favor of any of the foregoing proposals. That was the final proposal for today's meeting. I will now take a moment to review any questions submitted regarding the proposals before we close the polls. As a reminder, we will only review and answer questions at this time that pertain to the proposals. I will now look for any questions.

I do not see any questions. As there are no questions related to the proposals being presented to our stockholders for approval at today's meeting, the time is now 8:10 A.M. Pacific Time, and the polls are now closed for voting. May we have the results of the voting, please?